10x Genomics, Inc. Operating Income Loss

• 10x Genomics, Inc. showed an increase of +68.7% in Operating Income Loss from 2024 to 2025.
• This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), 10x Genomics, Inc.'s Operating Income Loss has declined by 231.9%.
• Historical annual values: Fiscal year 2025: -$60.99 million | Fiscal year 2024: -$194.56 million | Fiscal year 2023: -$265.33 million | Fiscal year 2022: -$167.94 million | Fiscal year 2021: -$52.25 million | Fiscal year 2020: -$534.14 million | Fiscal year 2019: -$30.57 million | Fiscal year 2018: -$110.76 million | Fiscal year 2017: -$18.38 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026